Drug Profile
Capromorelin
Alternative Names: CP-424391; CP-424391-18; RQ-00000005; RQ-5Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Pfizer
- Developer RaQualia Pharma; Shire; University of Melbourne
- Class Osteoporosis therapies; Pyrazolones; Small molecules
- Mechanism of Action Ghrelin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gastrointestinal disorders; Musculoskeletal disorders
Highest Development Phases
- No development reported Gastrointestinal disorders; Musculoskeletal disorders